8-K: Bio-Path Holdings Provides Clinical Update and Expansion Plans, Including Obesity Program

Bio-Path Holdings announces progress in its clinical trials, development of molecular biomarkers, and expansion into preclinical obesity studies.

Summary

• Bio-Path Holdings is advancing its clinical programs, including a Phase 2 trial for Acute Myeloid Leukemia (AML) and several Phase 1/1b trials for solid tumors and blood cancers.
• The company has developed molecular biomarkers to improve patient selection in its oncology studies, aiming to increase the probability of treatment success.
• Bio-Path is expanding its research into obesity, with preclinical studies planned for prexigebersen, leveraging its existing safety data from leukemia trials.
• The Phase 2 AML trial is currently paused for interim analysis, amendment preparation, and FDA review, with enrollment expected to complete in the next 18 months for the first two cohorts.
• The company is progressing through dose levels in its Phase 1/1b trials for BP1001-A and BP1002, with plans to advance to higher dose levels by the end of the year.
• Bio-Path is also developing BP1003 for advanced solid tumors, with plans for a Phase 1 study in refractory metastatic solid tumors.
• The company believes prexigebersen has potential for treating obesity and obesity-related cancers due to its mechanism of action and existing safety data.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with progress in multiple clinical trials and expansion into new therapeutic areas, but also acknowledges risks and delays, resulting in a moderately positive sentiment.

Positives

• The development of molecular biomarkers could improve the success rate of clinical trials by identifying patients more likely to respond to treatment.
• The expansion into obesity research leverages existing safety data and opens up a large potential market.
• Advancement to higher dose levels in multiple Phase 1/1b trials indicates positive safety profiles for the drug candidates.
• The company has multiple ongoing clinical trials across different cancer types, diversifying its pipeline.
• The potential for prexigebersen to treat obesity and obesity-related cancers could significantly expand its market potential.

Negatives

• The Phase 2 AML trial is currently paused, which could delay the timeline for this program.
• The company is still in early stages of clinical development, with no products yet approved for commercial use.
• The company is reliant on raising additional capital to continue its operations and clinical trials.

Risks

• The company's ability to raise additional capital is crucial for continued operations and clinical development.
• Clinical trial results may not be consistent with earlier stage studies, potentially impacting the success of the programs.
• The company faces risks related to intellectual property rights and the issuance of patents.
• Global pandemics, such as COVID-19, could impact the company's operations and clinical trials.
• The company is subject to regulatory risks, including FDA approvals and reviews.

Future Outlook

Bio-Path plans to continue advancing its clinical programs, including completing enrollment in ongoing trials, advancing to higher dose levels, and initiating preclinical studies for obesity. The company also plans to file an IND for BP1003.

Management Comments

• The Bio-Path team continues to work diligently toward advancing our important clinical work and have made meaningful progress in a number of areas critical to each program's success, said Peter H. Nielsen, President and Chief Executive Officer of Bio-Path.
• With the increased clinical data that we have generated, we are now able to develop the biomarkers needed to incorporate into our oncology studies.
• The incremental advances that we are making across these programs collectively push our DNAbilize platform closer to delivering these medicines to patients.
• Moreover, we are continuing to see the broader potential of our platform beyond oncology and look forward to realizing its potential across multiple indications, starting with obesity, continued Mr. Nielsen.

Industry Context

The development of molecular biomarkers is a growing trend in oncology, and Bio-Path's efforts align with this industry shift. The expansion into obesity research reflects a broader interest in addressing metabolic diseases with novel therapies. The company's focus on RNAi technology is also consistent with the industry's pursuit of targeted therapies.

Comparison to Industry Standards

• The use of molecular biomarkers to improve patient selection is becoming a standard practice in oncology clinical trials, similar to companies like Foundation Medicine and Guardant Health.
• The development of RNAi therapeutics is a competitive field, with companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals leading the way, but Bio-Path's unique DNAbilize platform offers a differentiated approach.
• The expansion into obesity research is a strategic move, as the market for weight loss drugs is large and growing, with companies like Novo Nordisk and Eli Lilly dominating the space, but Bio-Path's approach is novel.
• The median survival rates for AML patients mentioned in the document (5-10 months for older patients unable to receive intensive chemotherapy and less than 3 months for those failing frontline venetoclax-based therapy) are consistent with industry benchmarks for these patient populations.

Stakeholder Impact

• Shareholders may view the clinical progress and expansion into obesity research positively.
• Employees may be motivated by the company's progress and expansion plans.
• Patients may benefit from the development of new therapies for cancer and obesity.
• Suppliers and creditors may be impacted by the company's financial performance and ability to raise capital.

Next Steps

• Complete enrollment in cohorts 1 and 2 of the Phase 2 AML study over the next eighteen months.
• Advance to dose level 3 in the Phase 1/1b trial of BP1001-A by year-end.
• Advance to dose level 3 in the Phase 1/1b trial of BP1002 in the fourth quarter of 2024.
• Complete enrollment and review data for the second dose cohort of BP1002 in lymphoma and CLL by year-end.
• Conduct preclinical studies evaluating prexigebersen for the treatment of obesity.
• Conduct additional Investigational New Drug (IND)-enabling studies with an aim to advance prexigebersen into first-in-human studies in obesity.
• File an IND for BP1003.

Key Dates

Keywords

clinical trials, biomarkers, oncology, obesity, prexigebersen, AML, solid tumors, BP1001-A, BP1002, BP1003, DNAbilize, RNAi, liposomal delivery, antisense technology